40 results
10-K
2022 FY
EX-4.7
VYNT
Vyant Bio, Inc.
Annual report
31 Mar 23
12:00am
10-K
2021 FY
EX-4.7
VYNT
Vyant Bio, Inc.
Annual report
30 Mar 22
7:27am
8-K
EX-4.1
VYNT
Vyant Bio, Inc.
5 Apr 21
Report of Independent Registered Public Accounting Firm
5:12pm
10-K
2020 FY
EX-4.14
VYNT
Vyant Bio, Inc.
Annual report
31 Mar 21
6:01am
8-K
EX-4.1
VYNT
Vyant Bio, Inc.
16 Feb 21
Cancer Genetics Announces $17.5 Million Common Stock Offering Priced At-the-Market under Nasdaq Rules
4:51pm
8-K
EX-4.3
0455pu3u
1 Feb 21
Cancer Genetics Announces $10.0 Million Private Placement Priced At-the-Market
5:24pm
8-K
EX-4.1
v1gec6e
1 Feb 21
Cancer Genetics Announces $10.0 Million Private Placement Priced At-the-Market
5:24pm
8-K
EX-4.1
cj8nuj zwrvt0u6eaq4t
2 Nov 20
Cancer Genetics, Inc. Announces $2.0 Million Bought Deal Offering
4:26pm
425
EX-4.1
cwwfr3e
2 Nov 20
Business combination disclosure
4:24pm
8-K
EX-4.1
n1r 8eoog0toedj
25 Oct 19
Cancer Genetics, Inc. Announces Strategic Transactions
12:00am
8-K
EX-4.1
igg7ow gt
19 Jul 19
Cancer Genetics, Inc. Announces Strategic Transactions
5:30pm
8-K
EX-4.1
pw3zsby
29 Jan 19
Unregistered Sales of Equity Securities
5:25pm
8-K
EX-4.1
1qlmjj g3vyi
10 Jan 19
Cancer Genetics, Inc. Announces Proposed Public Offering of Common Stock
5:04pm
8-K
EX-4.1
gnni0r nyq7i2cxidoe
18 Jul 18
Cancer Genetics Closes $2.625 million Convertible Note Financing
4:18pm
8-K
EX-4.1
9fy847tacsqpx zv6h4x
5 Jul 18
Entry into a Material Definitive Agreement
4:59pm
8-K
EX-4.1
pt73u6lz80sh
8 Dec 17
Cancer Genetics Prices $7.0 Million Registered Direct Offering
12:00am
8-K
EX-4.1
a4yv qlwl3
16 Aug 17
Entry into a Material Definitive Agreement
12:00am